Notice: This company has been marked as potentially delisted and may not be actively trading. VBI Vaccines (VBIV) News Today Add Compare Share Share Headlines Stock AnalysisEarningsHeadlinesInsider TradesSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period VBI Vaccines Restructures and Acquired by K2 VBI TrustJanuary 3, 2025 | tipranks.comVBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company OperationsNovember 15, 2024 | businesswire.comWhy Is VBI Vaccines (VBIV) Stock Up 62% Today?August 6, 2024 | investorplace.comVBI Vaccines to be delisted from Nasdaq following restructuringAugust 4, 2024 | investing.comVBI Vaccines Provides an Update on its Restructuring ProceedingsAugust 3, 2024 | finance.yahoo.comVBI Vaccines secures court protection for restructuringAugust 1, 2024 | investing.comVBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic AlternativesJuly 30, 2024 | stockhouse.comVBI Vaccines Announces Results of Annual General MeetingJune 25, 2024 | businesswire.comVBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma PatientsMay 29, 2024 | businesswire.comVBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma PatientsMay 22, 2024 | businesswire.comVBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | investorplace.comVBI Vaccines Reports First Quarter 2024 Financial ResultsMay 15, 2024 | businesswire.comVBI Vaccines Reports Full Year 2023 Financial ResultsApril 16, 2024 | businesswire.comVBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 11, 2024 | businesswire.comVBI Vaccines secures $2 million in direct offeringApril 11, 2024 | investing.comVBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 9, 2024 | businesswire.comVBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent GlioblastomaApril 3, 2024 | businesswire.comVBI Vaccines expands collaboration with Canadian governmentApril 2, 2024 | msn.comVBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine PlatformApril 2, 2024 | businesswire.comVBI Vaccines Inc. (VBIV)March 31, 2024 | finance.yahoo.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsMarch 22, 2024 | finance.yahoo.comNorth Carolina biotech inks $30M deal to expand its global pipelineFebruary 15, 2024 | bizjournals.comVBI signs deal to sell manufacturing capabilities, certain assets with Brii BiosciencesFebruary 14, 2024 | msn.comStrategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI VaccinesFebruary 14, 2024 | finance.yahoo.comWhy Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving PremarketFebruary 14, 2024 | benzinga.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 14, 2024 | finance.yahoo.comVBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii BiosciencesFebruary 14, 2024 | businesswire.comBrii Biosciences To Buy VBI's IP Rights In BRII-179February 13, 2024 | markets.businessinsider.comBrii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial SuppliesFebruary 13, 2024 | prnewswire.comVBI Vaccines Secures Forbearance Agreement ExtensionsFebruary 7, 2024 | msn.comVBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual MeetingNovember 20, 2023 | finance.yahoo.comVBI Vaccines Non-GAAP EPS of -$0.38, revenue of $6.62M misses by $6.63MNovember 14, 2023 | msn.comVBI Vaccines Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comVBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine ProgramOctober 26, 2023 | finance.yahoo.comThese Are the Side Effects You Can Expect From the New COVID Vaccine, According to ImmunologistsSeptember 30, 2023 | yahoo.comVBI Vaccines’ pan-coronavirus vaccine candidate produced broad protection against COVID variants of concernSeptember 27, 2023 | msn.comVBI Vaccines To Advance Coronavirus Vaccine ProgramSeptember 27, 2023 | markets.businessinsider.comVBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of ConcernSeptember 27, 2023 | finance.yahoo.comVBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBMSeptember 7, 2023 | finance.yahoo.comVBI Vaccines gains after Phase 2 data for Hep B candidateSeptember 6, 2023 | msn.comVBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis BSeptember 6, 2023 | finance.yahoo.comVBI Vaccines GAAP EPS of -$5.05 misses by $2.89, revenue of $0.74M misses by $0.19MAugust 14, 2023 | seekingalpha.comVBI Vaccines Reports Second Quarter 2023 Financial ResultsAugust 14, 2023 | finance.yahoo.comVBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common SharesJuly 24, 2023 | finance.yahoo.com7 Biotech Stocks to Sell in JulyJuly 19, 2023 | finance.yahoo.comDurham biotech secures global rights to hepatitis B treatmentJuly 10, 2023 | bizjournals.comVBI Vaccines Stock Cut in Half after Announcing Public OfferingJuly 6, 2023 | msn.comVBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct OfferingJuly 6, 2023 | finance.yahoo.comWhy Is VBI Vaccines (VBIV) Stock Down 40% Today?July 6, 2023 | investorplace.comBrii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to CureJuly 6, 2023 | benzinga.com Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address VBIV Media Mentions By Week VBIV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VBIV News Sentiment▼0.000.64▲Average Medical News Sentiment VBIV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VBIV Articles This Week▼00▲VBIV Articles Average Week Get VBI Vaccines News Delivered to You Automatically Sign up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Conduit Pharmaceuticals News Today RedHill Biopharma News Today NLS Pharmaceutics News Today Virax Biolabs Group News Today ABVC BioPharma News Today Eyenovia News Today Galecto News Today Viracta Therapeutics News Today Orgenesis News Today Evoke Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VBIV) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VBI Vaccines Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VBI Vaccines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
